Join the club for FREE to access the whole archive and other member benefits.

Contract award for the supply of DPYD testing kits to NHS Wales

Technology suitable for meeting the lab requirements to deliver the service


Key points from article :

Elucigene DPYD is a simple-to-use genotyping test.

To identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency.

Cause side effects in patients treated with chemotherapeutic drug 5-Fluorouracil (5-FU).

5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.

The Elucigene DPYD screens cancer patients prior to the start of treatment with 5-FU.

To identify the risk of severe side effects.

Wales was the first nation in the UK to routinely implement this screening.

All Wales Genomics Laboratory deems the Company’s oncology product.

The only technology suitable for meeting the lab requirement.

Allowing the Company to eliminate an extensive tender process.

Yourgene Health Awarded £232K Contract.

To Supply Oncology Genotyping Testing Kits to NHS Wales.

Lyn Rees, CEO of Yourgene says

"Extremely pleased to award this tender to supply our IVD-marked oncology product to NHS Wales..."

Mentioned in this article:

Click on resource name for more details.

All Wales Medical Genomics Service (AWMGS)

NHS specialist regional health service to help and support patients in Wales who have genetic conditions

Lyn Rees

Seasoned executive in global healthcare and IVD markets

Yourgene Health

Molecular diagnostics group which develops and commercialises genetic products and services to positively impact human health

Topics mentioned on this page:
Precision Medicine, Cancer